Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07.

Miso KimBhumsuk KeamChan-Young OckSe Hyun KimYu Jung KimSun Min LimJin-Soo KimTae Min KimSook-Hee HongMi Sun AhnSeong Hoon ShinEun Joo KangDong Wan KimSun-Wha ImJong-Il KimJong Seok LeeJoo-Hang KimDae Seog Heo

Published in: Thoracic cancer (2020)

Durvalumab and tremelimumab demonstrated clinical benefit with a prolonged survival and manageable toxicity profile in patients with recurrent or metastatic PSC.

Keyphrases

phase ii study
open label
locally advanced
squamous cell carcinoma
pulmonary hypertension
small cell lung cancer
oxidative stress
placebo controlled
randomized controlled trial
clinical trial
double blind